Abstract
In the article cited above, the authors miscategorized CD59 as a transmembrane protein when it is in fact a glycosylphosphatidylinositol-anchored surface protein. The sentence on page 2367 in the last paragraph of the first column was corrected to read: CD59, a major regulator of the complement activity, is a glycosylphosphatidylinositol- anchored membrane protein that binds to the C5-8 complex and inhibits assembly of C9 monomers into the terminal complement complex, thus protecting cells from complement-mediated injury (33). The error does not change the results or conclusions of the article. The online version of the article has been corrected to reflect these changes.
| Original language | English (US) |
|---|---|
| Number of pages | 1 |
| Journal | Diabetes Care |
| Volume | 42 |
| Issue number | 6 |
| DOIs |
|
| State | Published - Nov 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
Cite this
Erratum : Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes (Diabetes Care (2018) 41 (2361-2369) DOI: 10.2337/dc18-0699). / Vaisar, Tomas; Durbin-Johnson, Blythe; Whitlock, Kathryn; Babenko, Ilona; Mehrotra, Rajnish; Rocke, David M; Afkarian, Maryam.
In: Diabetes Care, Vol. 42, No. 6, 01.11.2018.Research output: Contribution to journal › Comment/debate
}
TY - JOUR
T1 - Erratum
T2 - Urine complement proteins and the risk of kidney disease progression and mortality in type 2 diabetes (Diabetes Care (2018) 41 (2361-2369) DOI: 10.2337/dc18-0699)
AU - Vaisar, Tomas
AU - Durbin-Johnson, Blythe
AU - Whitlock, Kathryn
AU - Babenko, Ilona
AU - Mehrotra, Rajnish
AU - Rocke, David M
AU - Afkarian, Maryam
PY - 2018/11/1
Y1 - 2018/11/1
N2 - In the article cited above, the authors miscategorized CD59 as a transmembrane protein when it is in fact a glycosylphosphatidylinositol-anchored surface protein. The sentence on page 2367 in the last paragraph of the first column was corrected to read: CD59, a major regulator of the complement activity, is a glycosylphosphatidylinositol- anchored membrane protein that binds to the C5-8 complex and inhibits assembly of C9 monomers into the terminal complement complex, thus protecting cells from complement-mediated injury (33). The error does not change the results or conclusions of the article. The online version of the article has been corrected to reflect these changes.
AB - In the article cited above, the authors miscategorized CD59 as a transmembrane protein when it is in fact a glycosylphosphatidylinositol-anchored surface protein. The sentence on page 2367 in the last paragraph of the first column was corrected to read: CD59, a major regulator of the complement activity, is a glycosylphosphatidylinositol- anchored membrane protein that binds to the C5-8 complex and inhibits assembly of C9 monomers into the terminal complement complex, thus protecting cells from complement-mediated injury (33). The error does not change the results or conclusions of the article. The online version of the article has been corrected to reflect these changes.
UR - http://www.scopus.com/inward/record.url?scp=85066456138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066456138&partnerID=8YFLogxK
U2 - 10.2337/dc19-er06a
DO - 10.2337/dc19-er06a
M3 - Comment/debate
C2 - 30936112
AN - SCOPUS:85066456138
VL - 42
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 6
ER -